Pituitary function in normoprolactinaemic infertile men receiving bromocriptine.

Area of Science:

• Endocrinology
• Reproductive Medicine
• Clinical Trials

Background:

• Hyperprolactinemia is a known cause of infertility in men.
• The efficacy of bromocriptine in infertile men with normal prolactin levels is not well-established.
• Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) play crucial roles in male reproductive function.

Purpose of the Study:

• To investigate the effects of bromocriptine on hormonal profiles and sperm parameters in infertile men with normal prolactin levels.
• To assess the impact of bromocriptine on gonadotropin (FSH and LH) secretion and responsiveness.
• To evaluate changes in sperm density, volume, and motility following bromocriptine treatment.

Main Methods:

• A double-blind, placebo-controlled trial involving ten infertile men.
• Participants received either bromocriptine (7.5 mg daily) or a placebo for 4 months.
• Hormonal levels (prolactin, TSH, testosterone, LH, FSH) were measured at baseline and after treatment.
• Hormonal responses to TRH and LHRH stimulation tests were assessed.

Main Results:

• Bromocriptine significantly reduced plasma prolactin levels under basal conditions and after TRH stimulation (P < 0.01).
• No significant changes were observed in basal plasma gonadotropins (FSH, LH), testosterone, or TSH levels.
• Sperm density, volume, and motility remained unchanged.
• A trend towards reduced LH response to LHRH was noted in the bromocriptine group, but it did not reach statistical significance compared to placebo.

Conclusions:

• Prolonged bromocriptine therapy in normoprolactinaemic men does not suppress FSH secretion.
• Any observed reduction in LH responsiveness to LHRH is not associated with a significant decrease in plasma testosterone.
• Bromocriptine is unlikely to be beneficial for male infertility solely due to its prolactin-lowering effects in men with normal prolactin levels.